Key Takeaways
- First-quarter revenue reached $15.29B, surpassing the $14.94B consensus forecast
- Core earnings per share of $2.58 exceeded analyst projections of $2.54
- Cancer treatment sales increased 16% compared to last year; rare disease segment grew 15%
- Annual outlook unchanged: anticipating mid-to-high single-digit revenue expansion, low double-digit core EPS increase
- Shares declined approximately 1% following the announcement, with market watchers noting strong performance already reflected in valuation
The British pharmaceutical giant AstraZeneca delivered first-quarter results Wednesday that topped analyst expectations, yet investors responded with indifference. The company reported quarterly revenue of $15.29 billion, marking an increase from $13.59 billion in the same period last year and exceeding Wall Street’s $14.94 billion projection.
AstraZeneca $AZN Q1 revenue rose to $15.29B, above the $14.94B estimate, as strong cancer and rare-disease drug sales lifted results. Oncology now makes up about 44% of revenue. Core EPS was $2.58 vs. $2.54 est., and the company kept full-year guidance.
— Wall St Engine (@wallstengine) April 29, 2026
Core earnings per share reached $2.58, outperforming the $2.54 consensus estimate. Core operating profit climbed 12% to reach $4.25 billion.
However, the positive earnings surprise didn’t translate to stock gains, with AZN shares declining roughly 1% during morning London trading hours. Adam Vettese, an analyst at eToro, characterized the market response as “muted,” explaining that the company’s strong performance trajectory had already been factored into the current share price.
The oncology division continues to serve as the company’s primary growth driver, representing 44% of total revenue. The cancer treatment segment generated $6.8 billion in sales, reflecting a 16% year-over-year increase at constant currency rates.
Imfinzi, a treatment for bladder and lung malignancies, saw sales jump 30% to reach $1.7 billion. Tagrisso, prescribed for lung cancer patients, increased 5% to $1.8 billion. Enhertu, which treats breast and gastric cancers, experienced a remarkable 34% surge to $831 million.
The company’s rare disease division also posted strong performance, with sales climbing 15% year-over-year.
Oncology and Rare Diseases Fuel Growth
Revenue from the United States expanded 10% during the quarter, while Chinese market sales increased 2%. AstraZeneca has executed significant strategic initiatives in both territories recently, including a $50 billion U.S. manufacturing agreement and a $15 billion investment commitment in China.
The pharmaceutical company also obtained a New York Stock Exchange listing and benefited from U.S. tariff exemptions through a drug pricing arrangement.
Net income for the first quarter increased to $3.08 billion from $2.92 billion in the prior-year period.
Development Pipeline and Long-Term Vision Remain Intact
Chief Executive Pascal Soriot reaffirmed the organization’s ambitious goal of achieving $80 billion in annual revenue by 2030. He indicated that AstraZeneca is gearing up for numerous product launches and remains positioned to introduce more than 20 new therapies by that target date.
Three new medications could receive U.S. market authorization this year subject to regulatory clearance: baxdrostat for treating hypertension, camizestrant for a specific breast cancer variant, and gefurulimab for a chronic autoimmune condition.
The company maintained its full-year 2026 financial guidance without revision. AstraZeneca continues to anticipate mid-to-high single-digit revenue growth and low double-digit core earnings per share expansion at constant exchange rates.
Last week, Soriot cautioned that Europe risks becoming merely a “sales office” for the global pharmaceutical sector as it lags behind the United States and China in innovation and investment. This observation provides context for AstraZeneca’s ongoing efforts to strengthen its presence in both competitive markets.
LSEG analysts project full-year 2026 sales growth of 7.2% and profit expansion of 11.2%, closely aligned with 2025 performance metrics.
AstraZeneca shares have remained relatively unchanged year-to-date prior to today’s earnings announcement. The better-than-expected results did little to alter that trajectory.
